Article: Nicotinamide Riboside Decreased DNA Damage in Liver Cells: Preclinical Findings

PrevNext
Cancer Liver Disease Liver Health Preclinical

Nicotinamide Riboside Decreased DNA Damage in Liver Cells: Preclinical Findings

Synopsis

Hepatocellular carcinoma (HCC) is a fast-growing liver cancer, but its exact origin has been unclear. Using human data and mouse models, researchers found that HCC starts mainly from liver cells called hepatocytes. However, in some situations, liver progenitor cells (HPCs)—which help regenerate the liver—can also form tumors, including aggressive HCCs. The study showed that signals from cancerous hepatocytes, including galectin-3 and α-ketoglutarate, tell HPCs to stay immature and grow into cancer cells. Blocking galectin-3 in mice reduced tumor formation, and high galectin-3 levels in human tumors were linked to worse survival. These findings could help guide liver cancer treatments and improve understanding of liver regeneration.

Journal

Cell Reports

Share

Read more

COVID/Long-COVID

NAD+ Biosynthesis Enzyme Protects Aortic Smooth Muscle Cells: Preclinical Findings

Synopsis The walls of the aorta weaken with age and stress, risking serious damage. Smooth muscle cells (SMCs) in the aorta need NAD+, made by the enzyme NAMPT, for health. In humans with aortic d...

Read more
Liver Health

Nicotinamide Riboside Prevents and Reverses Chemotherapy-Induced Peripheral Neuropathy: Preclinical Findings

Synopsis Damage to sensory nerves can cause peripheral neuropathy after chemotherapy. Increasing levels of nicotinamide adenine dinucleotide (NAD+) can protect nerves from injury. This study teste...

Read more